Y. Ohashi

Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia

T. Ogihara, R. Morishita, T. Yamaguchi, 2010, Gene Therapy.

SY1. building the foundation for investigator-initiated clinical trial

P. Jänne, H. Katayama, M. Kudo, 2012 .

Serum leptin levels are associated with hyperinsulinemia independent of body mass index but not with visceral obesity.

Y. Yazaki, T. Yamaguchi, T. Katakura, 1997, Biochemical and biophysical research communications.

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

K. Eguchi, J. Furuse, M. Ikeda, 2014, Investigational New Drugs.

A mutation of the b3-adrenergic receptor is associated with visceral obesity but decreased serum triglyceride

Y. Yazaki, A. Shuldiner, T. Yamaguchi, 1997, Diabetologia.

The Gln27Glu beta2-adrenergic receptor variant is associated with obesity due to subcutaneous fat accumulation in Japanese men.

Y. Yazaki, T. Kadowaki, Y. Akanuma, 1999, Biochemical and biophysical research communications.

Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer

H. Ueno, J. Furuse, K. Mizumoto, 2017, Journal of Cancer Research and Clinical Oncology.

REVERCE: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan: Quality of life analysis.

E. Oki, T. Yamanaka, J. Furuse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.